SVB Wealth LLC Trims Stock Holdings in IQVIA Holdings Inc. $IQV

SVB Wealth LLC cut its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 39.3% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,434 shares of the medical research company’s stock after selling 4,807 shares during the quarter. SVB Wealth LLC’s holdings in IQVIA were worth $1,171,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in IQV. Clal Insurance Enterprises Holdings Ltd increased its stake in shares of IQVIA by 436.7% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock worth $28,000 after buying an additional 131 shares during the last quarter. Trust Co. of Toledo NA OH acquired a new position in IQVIA during the 2nd quarter worth $39,000. J.Safra Asset Management Corp increased its position in shares of IQVIA by 208.6% in the 2nd quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock worth $39,000 after purchasing an additional 169 shares during the last quarter. Rothschild Investment LLC lifted its position in shares of IQVIA by 85.5% during the second quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock worth $42,000 after purchasing an additional 124 shares during the last quarter. Finally, NewSquare Capital LLC increased its holdings in IQVIA by 185.3% in the second quarter. NewSquare Capital LLC now owns 291 shares of the medical research company’s stock valued at $46,000 after buying an additional 189 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Trading Down 2.4%

IQVIA stock opened at $218.20 on Wednesday. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $234.29. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $37.16 billion, a price-to-earnings ratio of 29.93, a PEG ratio of 2.51 and a beta of 1.37. The firm has a 50-day moving average price of $215.90 and a two-hundred day moving average price of $188.23.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. During the same period in the prior year, the company posted $2.84 EPS. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have commented on IQV. HSBC raised IQVIA from a “hold” rating to a “buy” rating and increased their target price for the stock from $195.00 to $235.00 in a report on Thursday, October 9th. Jefferies Financial Group upgraded IQVIA from a “hold” rating to a “buy” rating and raised their price objective for the stock from $195.00 to $225.00 in a research note on Tuesday, September 9th. Barclays boosted their target price on shares of IQVIA from $185.00 to $200.00 and gave the company an “equal weight” rating in a research note on Thursday, October 2nd. Weiss Ratings restated a “hold (c)” rating on shares of IQVIA in a research report on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Saturday. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and an average target price of $241.44.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the transaction, the insider owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.60% of the stock is owned by corporate insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.